(Q37761370)

English

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

scientific article published on August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

Europe PubMed Central

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Hermann Einsele

20

object named as

Hermann Einsele

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Antonio Palumbo

21

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

19

object named as

Aaron Polliack

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Monika Engelhardt

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Martina Kleber

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Josefina Udi

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Ralph Wäsch

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Andrew Spencer

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Francesca Patriarca

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Stefan Knop

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Benedetto Bruno

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Martin Gramatzki

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Fortunato Morabito

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Martin Kropff

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Orhan Sezer

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Donald Bunjes

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Mario Boccadoro

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Christian Straka

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 August 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

number of pages

20

1 reference

based on heuristic

inferred from page(s)

Leukemia & Lymphoma

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

51

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1424-1443

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

State of the art therapy in multiple myeloma and future perspectives

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Characterization of in vitro growth of multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

160 years of multiple myeloma: progress and challenges

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Guidelines on the diagnosis and management of multiple myeloma 2005.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Current multiple myeloma treatment strategies with novel agents: a European perspective

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Autologous hematopoietic stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Role of autologous and allogeneic stem cell transplantation in myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Strategies to improve the outcome of stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Characterization of clonogenic multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Induction of angiogenesis by normal and malignant plasma cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Relapse/Refractory myeloma patient: potential treatment guidelines.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A systematic review of the role of bisphosphonates in metastatic disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Prevention of infections and thromboses after splenectomy or because of functional loss of the spleen

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

MicroRNA signatures in human cancers

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Early genetic events provide the basis for a clinical classification of multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37761370&oldid=2109062049"